LAS VEGAS , NV, UNITED STATES, February 12, 2025 /EINPresswire / -- DelveInsight's“Pancreatic Ductal Adenocarcinoma market Insights, Epidemiology, and Market Forecast-2032” report offers an in ...

Purpose: Hypodensity of pancreatic ductal adenocarcinoma (PDAC) during contrast-enhanced computed tomography (CECT) examination is common, but a minority of PDAC patients exhibit hyperdense images.

He noted that other assays studied in pancreatic cancer have only examined a handful of samples. "When they publish a second ...

jhmi.edu Objective Although pancreatic ductal adenocarcinoma is considered a rapidly progressive disease, mathematical models estimate that it takes many years for an initiating pancreatic cancer cell ...

A new blood test could help doctors detect pancreatic cancer earlier, potentially improving survival rates for one of the ...

Pancreatic Ductal Carcinoma Market Outlook 2025-2035: The pancreatic ductal carcinoma market is demonstrating a promising trajectory, with a projected CAGR of 5.83% across the 7 major markets between ...

Penpulimab is under clinical development by Akeso and currently in Phase II for Metastatic Adenocarcinoma of The Pancreas. According to GlobalData, Phase II drugs for Metastatic Adenocarcinoma of The ...

A retrospective chart review was performed of patients with pancreatic cancer treated at the Johns Hopkins Hospital between January 2021 and December 2023. During their initial clinic visit, patients ...

Phase II study of niraparib and dostarlimab for the treatment of germline or somatic homologous recombination repair mutated (HRD) metastatic pancreatic cancer.

Clinical presentation is often identical to that of pancreatic adenocarcinoma. Preoperative diagnosis of primary pancreatic sarcoidosis is always challenging. We present a 52-year-old man who ...

Budigalimab is under clinical development by AbbVie and currently in Phase II for Metastatic Adenocarcinoma of The Pancreas. According to GlobalData, Phase II drugs for Metastatic Adenocarcinoma of ...